clinical trial · NCT07158827
Expanded Access to Tavapadon
AbbVie·—·available
Parkinson DiseaseTavapadon
brief summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to tavapadon prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
started
—
primary completion
—
completion
—
last updated
Feb 10, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol